CoChat

Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index

Open access
Buti, Sebastiano, Bersanelli, Melissa, Perrone, Fabiana, Tiseo, Marcello, Tucci, Marco, Adamo, Vincenzo, Stucci, Luigia S., Russo, Alessandro, Tanda, Enrica T., Spagnolo, Francesco, Rastelli, Francesca, Pergolesi, Federica, Santini, Daniele, Russano, Marco, Anesi, Cecilia, Giusti, Raffaele, Filetti, Marco, Marchetti, Paolo, Botticelli, Andrea, Gelibter, Alain, Occhipinti, Mario Alberto, Ferrari, Marco, Vitale, Maria Giuseppa, Nicolardi, Linda, Chiari, Rita, Rijavec, Erika, Nigro, Olga, Tuzi, Alessandro, De Tursi, Michele, Di Marino, Pietro, Conforti, Fabio, Queirolo, Paola, Bracarda, Sergio, Macrini, Serena, Gori, Stefania, Zoratto, Federica, Veltri, Enzo, Di Cocco, Barbara, Mallardo, Domenico, Vitale, Maria Grazia, Santoni, Matteo, Patruno, Leonardo, Porzio, Giampiero, Ficorella, Corrado, Pinato, David J., Ascierto, Paolo A., Cortellini, Alessio · 2021 · European Journal of Cancer
Cited by 115

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Abstract

BACKGROUND Concomitant medications are known to impact on clinical outcomes of patients treated with immune checkpoint inhibitors (ICIs). We aimed weighing the role of different concomitant baseline medications to create a drug-based prognostic score. METHODS We evaluated concomitant baseline medications at immunotherapy initiation for their impact on objective response rate (ORR), progression-free survival (PFS) and overall survival (OS) in a single-institution cohort of patients with advanced cancer treated with ICIs (training cohort, N = 217), and a drug-based prognostic score with the drugs resulting significantly impacting the OS was computed. Secondly, we externally validated the score in a large multicenter external cohort (n = 1012). RESULTS In the training cohort (n = 217), the median age was 69 years (range: 32-89), and the primary tumours were non-small-cell lung cancer (70%), melanoma (14.7%), renal cell carcinoma (9.2%) and others (6%). Among baseline medications, corticosteroids (hazard ratio [HR] = 2.3; 95% confidence interval [CI]: 1.60-3.30), systemic antibiotics (HR = 2.07; 95% CI: 1.31-3.25) and proton-pump inhibitors (PPIs) (HR = 1.57; 95% CI: 1.13-2.18) were significantly associated with OS. The prognostic score was calculated using these three drug classes, defining good, intermediate and poor prognosis patients. Within the training cohort, OS (p < 0.0001), PFS (p < 0.0001) and ORR (p = 0.0297) were significantly distinguished by the score stratification. The prognostic value of the score was also demonstrated in terms of OS (p < 0.0001), PFS (p < 0.0001) and ORR (p = 0.0006) within the external cohort. CONCLUSION Cumulative exposure to corticosteroids, antibiotics and PPIs (three likely microbiota-modulating drugs) leads to progressively worse outcomes after ICI therapy. We propose a simple score that can help stratifying patients in routine practice and clinical trials of ICIs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ejca.2020.09.033

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Cited by

See all 115

Metadata

Authors
Buti, S., Bersanelli, M., Perrone, F., Tiseo, M., Tucci, M., Adamo, V., Stucci, L. S., Russo, A., Tanda, E. T., Spagnolo, F., Rastelli, F., Pergolesi, F., Santini, D., Russano, M., Anesi, C., Giusti, R., Filetti, M., Marchetti, P., Botticelli, A., Gelibter, A., Occhipinti, M. A., Ferrari, M., Vitale, M. G., Nicolardi, L., Chiari, R., Rijavec, E., Nigro, O., Tuzi, A., De Tursi, M., Di Marino, P., Conforti, F., Queirolo, P., Bracarda, S., Macrini, S., Gori, S., Zoratto, F., Veltri, E., Di Cocco, B., Mallardo, D., Vitale, M. G., Santoni, M., Patruno, L., Porzio, G., Ficorella, C., Pinato, D. J., Ascierto, P. A., & Cortellini, A.
Venue
European Journal of Cancer
Publisher
Elsevier BV
Published
2021-01
Volume
142
Pages
18-28
ISSN
0959-8049 (ISSN-L)
OpenAlex
W3104583693
Cited by
115
References
17
FWCI
6.26
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index. https://app.cochat.ai/papers/10.1016/j.ejca.2020.09.033
The paper
Buti, S., Bersanelli, M., Perrone, F., Tiseo, M., Tucci, M., Adamo, V., Stucci, L. S., Russo, A., Tanda, E. T., Spagnolo, F., Rastelli, F., Pergolesi, F., Santini, D., Russano, M., Anesi, C., Giusti, R., Filetti, M., Marchetti, P., Botticelli, A., . . . Cortellini, A. (2021). Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2020.09.033

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.